Lilly/BMS halt Phase III trial of anticancer necitumumab over blood clot concerns
This article was originally published in Scrip
Executive Summary
Lilly and Bristol-Myers Squibb have stopped enrolment in one of their two global Phase III studies evaluating the anticancer necitumumab owing to a risk of it causing blood clots. A second Phase III trial of the antibody will continue after a safety committee evaluation judged that the observered adverse effects were trial-specific and not drug-specific